Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.
And here is our regular feature in which we highlight a different person each week. This time around, we note that Daiichi Sankyo hired Mark Rutstein as head, global oncology clinical development. Previously, he worked at Bristol Myers Squibb as vice president, oncology development. Before that, Rutstein was vice president, global oncology clinical development at Bayer Healthcare.
But all work and no play can make for a dull cancer drug development chief. So in his spare time, Rutstein likes to cycle indoors. “I love to strap on a heart monitor and see how I can achieve my heart rate goals and how many calories I burn in an hour. My aim is 1,000, but I’ve gotten up to 1,200 calories in an hour a few times. To do that, it requires relentless focus and the ability to stay just a little breathless for a long period of time… I can become introspective and kind of disconnect and focus on something other than work…”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect